非胰岛素降糖药对糖尿病患者骨代谢的影响  

Effects of non-insulin hypoglycemic agents on bone metabolism in diabetes mellitus patients

作　　者：褚雪颖 邢小平[1] 王鸥[1] 

机构地区：[1]中国医学科学院北京协和医学院北京协和医院内分泌科国家卫生和计划生育委员会内分泌重点实验室,北京100730

出　　处：《中华骨质疏松和骨矿盐疾病杂志》2017年第3期297-305,共9页Chinese Journal Of Osteoporosis And Bone Mineral Research

基　　金：国家自然科学基金(81270873;81100559);国家临床重点专科建设项目(WBYZ2011-873)

摘　　要：糖尿病及骨质疏松均为我国高患病率疾病。近年来糖尿病已成为严重的健康问题,全球已有超过2亿人患有2型糖尿病。2型糖尿病患者虽然大多无骨密度下降,但是骨折风险仍然增加,原因与疾病本身及其用药均相关。临床上多种口服降糖药对糖尿病患者骨代谢可能产生影响。为预防骨量减少或骨质疏松带来的严重并发症,应考虑各种降糖药对骨代谢的作用。本文综述各类非胰岛素降糖药对骨代谢的影响,以期为临床上制定糖尿病用药方案提供参考。Both diabetes mellitus （DM） and osteoporosis represent a disease with high prevalence. DM has become a significant burden in terms of healthcare costs and quality of life. There are more than 2 billion people around the world affected by type 2 DM. Although most of the type 2 diabetes patients are characterized by normal bone mineral density （ BMD）, the risk of fracture is high, which is related to the disease itself and therapies. There exist various categories of drugs that may have influence on bone. This review describes the effects of non-insulin hypoglycemic agents on bone metabolism and shed a light on clinical medication.

关 键 词：非胰岛素降糖药 骨代谢 骨折风险 

分 类 号：R681[医药卫生—骨科学]